Thursday, February 7, 2013
This week in
Pluripotent cell-specific inhibitors (PluriSIns) to reduce the tumorigenic
risk of stem cell-based therapies
that are selectively toxic to human pluripotent stem cells could reduce the
tumorigenic risk of stem cell-based therapies. Residual undifferentiated stem
cells in stem cell-derived cell therapies can lead to teratoma formation. A
screen of about 50,000 small molecules identified 15 PluriSIns that were
cytotoxic to human embryonic stem cells (ESCs) and induced pluripotent stem
(iPS) cells but not to differentiated cells derived from these stem cells. In
a mixture of differentiated and undifferentiated stem cells injected into
mice, none of the cell mixtures pretreated with the lead PluriSIn developed
teratomas, whereas all vehicle-treated cell mixtures did. Next steps include
examining the ability of PluriSIns to reduce the risk of teratoma formation in
Published online Feb. 7, 2013
Two patent applications
filed; available for licensing through Yissum,
the technology transfer company for The
Hebrew University of Jerusalem, and Roche
Ben-David, U. et al.
Cell Stem Cell; published online Jan. 9, 2013;
Contact: Nissim Benvenisty, The Hebrew University of Jerusalem,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]